Current Protocols

Principal Investigator: Dr. Michael A. Liss

  • Prostate MRI as a Screening Tool to Detect Prostate Cancer – HSC20150160H
  • Rapid PCR to Guide Antibiotic Therapy at the Time of Prostate Biopsy – HSC20160386H
  • Tissue Bank and Database for Urologic Diseases – HSC20050234H
  • Computer Assisted Assessment of Imaging and Biomarkers To Predict Genitourinary Mass Outcomes – HSC20150089H
  • Phase Ib Trial of Encapsulated Rapamycin (eRapa) in Prostate Cancer Patients under Active Surveillance – HSC20180371X
  • A Pivotal, Prospective, Three-Stage, Single-Arm study of Focal Ablation of the Prostate with NanoTherm ™ Therapy System for a Limited-Volume, Clinically Localized, Intermediate-Risk Prostate Cancer

Principal Investigator: Dr. Robert Svatek

  • Repository for Bladder and Genitourinary Cancer – HSC20120159H
  • Multi-Institutional Study to Evaluate DNA Methylation Markers for Detection of Primary Bladder Cancers in Urine Samples from a Cohort of Patients with Hematuria – HSC20160419H
  • A Phase III, Open-Label Study to Evaluate the Safety and Efficacy of INSTILADRIN® (rAd-IFN/Syn3) Administered Intravesically to Patients with High Grade, BCG Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) – HSC20160351H
  • A Randomized study of rapamycin combined with intravesical BCG in patients with non-muscle invasive bladder cancer
  • Surveillance for low and low-intermediate risk non-muscle invasive bladder cancer: A Pilot Study – HSC20160162H

Principal Investigator: Dr. Dharam Kaushik

  • Impact of Yoga As Complementary Therapy on Quality of Life, Pro-inflammatory, and Cellular Immune Biomarkers in Patients Undergoing Radical Prostatectomy: A Pilot Randomized-Controlled Trial – HSC2015406H
  • Radical Cystectomy Compared with Chemoradiation for Muscle Invasive Bladder Cancer: A Pilot, Randomized-Controlled Non-Inferiority Trial – 15620H
  • Clinical Evaluation of the ExoIntelliScore Prostate in men presenting for initial biopsy; additional confirmation study including the impact on decision-making and health economics. –  HSC2017067H

Principal Investigator: Dr. Timothy Tseng

  • The Role of miR21 in Patients Presenting to the Emergency Department with Acute Ureteral Stones – HSC20150840H